Citius Oncology (CTOR) Stock Price, News & Analysis

Company Overview

Citius Oncology (NASDAQ:CTOR) is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted cancer therapies. Established as a spin-out from Citius Pharmaceuticals in 2021, the firm leverages proprietary DNA-based therapeutic platforms to create novel oncology agents. Its mission is to address critical unmet needs in solid tumors by advancing candidates that combine precise tumor targeting with innovative mechanisms of action.

The company’s pipeline comprises multiple clinical-stage programs, including a DNA-intercalating small molecule designed to induce tumor cell death, a novel chlorotoxin-derived targeting peptide conjugate aimed at selectively binding and penetrating malignant tissue, and an immune-modulating biologic that activates innate pathways to enhance antitumor responses. These candidates are being evaluated across indications such as glioblastoma, pancreatic cancer and hepatic metastases.

In addition to in-house research and development, Citius Oncology engages in strategic partnerships with academic institutions and contract development organizations to accelerate preclinical and clinical studies. The company has established scalable manufacturing processes compliant with current Good Manufacturing Practices (cGMP) and is pursuing regional collaborations to support regulatory filings and market access in North America and Europe.

The leadership team brings extensive experience from major pharmaceutical and biotechnology companies, with expertise spanning oncology research, clinical development, manufacturing and regulatory affairs. Supported by a scientific advisory board of oncologists and translational researchers, the management team is focused on advancing its pipeline through key clinical milestones and preparing for eventual commercialization.

Key Stats

• Today's Range: $4.60 to $5.24
• 50-Day Range: $0.85 to $5.32
• 52-Week Range: $0.55 to $6.19
• Volume: 544,120 shs
• Average Volume: 1.25 million shs
• Market Capitalization: $337.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Citius Oncology Stock Analysis - MarketRank™

Citius Oncology scored higher than 8% of companies evaluated by MarketBeat, and ranked 886th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Citius Oncology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Citius Oncology has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Citius Oncology has a P/B Ratio of 7.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CTOR.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Citius Oncology does not currently pay a dividend.

Dividend Growth

Citius Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CTOR.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.37

News Sentiment

Citius Oncology has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Citius Oncology this week, compared to 0 articles on an average week.

Search Interest

6 people have searched for CTOR on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Citius Oncology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Citius Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.57% of the stock of Citius Oncology is held by insiders.

Percentage Held by Institutions

70.52% of the stock of Citius Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CTOR Stock Analysis - Frequently Asked Questions

How have CTOR shares performed this year?

Citius Oncology's stock was trading at $1.15 at the beginning of the year. Since then, CTOR shares have increased by 309.6% and is now trading at $4.71.

How were Citius Oncology's earnings last quarter?

Citius Oncology, Inc. (NASDAQ:CTOR) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02.

How do I buy shares of Citius Oncology?

Shares of CTOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Citius Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Oncology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Advanced Micro Devices (AMD), Broadcom (AVGO), Confluent (CFLT), Genius Sports (GENI) and Intel (INTC).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/07/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CTOR
• Previous Symbol: NASDAQ:CTOR
• CIK: 1851484
• Web: www.citiusonc.com
• Phone: 347-627-0058
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.00
• High Stock Price Target: $3.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: -36.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -53.88%
• Return on Assets: -18.86%

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 0.36
• Quick Ratio: 0.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.64 per share
• Price / Book: 7.36

Miscellaneous

• Outstanding Shares: 71,552,000
• Free Float: 68,282,000
• Market Cap: $337.01 million
• Optionable: N/A
• Beta: 3.06